Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.36 |
| ▸ | ADH5 | P11766 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263261 | 0.80 | HPGD (0.44) | ADORA2AADORA2BHPGDCHEK1ADH5 | |
| SCHEMBL2398404 | 0.80 | ITGB1 (0.47) | ADORA2AADORA2BCSNK2A1HPGDITGB1 | |
| SCHEMBL12263336 | 0.72 | ITGB1 (0.46) | HPGDITGB1ITGA4 | |
| SCHEMBL7223616 | 0.72 | KDM5A (0.40) | KDM5AKDM5BCSNK2A1 | |
| Lithium SCHEMBL31165628 | 0.71 | ALDH1A1 (0.40) | KDM5AKDM5B | |
| SCHEMBL12263299 | 0.70 | ITGB1 (0.46) | ADORA2AADORA2BHPGDITGB1ITGA4 | |
| SCHEMBL20962586 | 0.69 | PDE4A (0.39) | P2RX3KDM5AHPGD | |
| SCHEMBL21924449 | 0.68 | PDE4A (0.33) | KDM5AKDM5BHPGD | |
| SCHEMBL31618312 | 0.67 | PTGS2 (0.48) | IDO1 | |
| SCHEMBL28540060 | 0.67 | HTR7 (0.46) | HPGDADH5IDO1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | F12, F2, SERPINC1 | P2RX3 4516/4885ADORA2A 4854/4885ADORA2B 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.